(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 1,384.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Argenx Se's revenue in 2025 is $1,917,647.On average, 10 Wall Street analysts forecast ARGX's revenue for 2025 to be $241,328,929,537, with the lowest ARGX revenue forecast at $219,466,783,552, and the highest ARGX revenue forecast at $260,408,526,253. On average, 10 Wall Street analysts forecast ARGX's revenue for 2026 to be $315,727,302,475, with the lowest ARGX revenue forecast at $291,255,211,944, and the highest ARGX revenue forecast at $348,114,674,527.
In 2027, ARGX is forecast to generate $381,667,860,871 in revenue, with the lowest revenue forecast at $351,276,246,191 and the highest revenue forecast at $399,586,037,758.